Fundamental analysis by حمید کوشکی(تحلیل کاربردی) about Stock دلقما on 8/12/2025

🔰 Loghman Pharmacy Since the mid -year, the market for injecting and antibiotics, which was unnecessary, has grown again. The group's four best -selling drugs were sold in the market last year, and in the first four months of this year, nearly two were sold. These drugs are also among the main products of Loghman, so their market boom is good for the company. ❇️ But risks: High dependence on a pharmaceutical family: Since the major production line of the company is related to antibiotics and cannot produce any other drug, any change in policymaking or the entry of a serious and new competitor can quickly be effective. 📌 Sales stability: It was good and the company's profitability depends on that it can be consistent in production and sales. And in some way, if sales are reduced, it cannot achieve its goals. #Children 🌐 Applied Fundamental Analysis/ Funds